Associations between the DBH gene, plasma dopamine β-hydroxylase activity and cognitive measures in Han Chinese patients with schizophrenia
Introduction
Cognitive impairment is a core, stable feature of schizophrenia that limits patient functioning and well-being (Keefe and Harvey, 2012) and associates with poor functional outcome (Fervaha et al., 2014, Kontaxaki et al., 2014). Studies also indicate that cognitive deficits occur prior to the onset of other symptoms of schizophrenia, and generally persist during the course of the illness (Dickerson et al., 2004, Hughes et al., 2003). Almost all individuals diagnosed with schizophrenia have some degree of cognitive impairment (Keefe et al., 2005).
Although the presence and impact of cognitive deficits in individuals with schizophrenia have been widely recognized, the underlying neurobiological mechanisms remain mostly unknown. Metabolic dysfunction in catecholamine neurotransmitters is important in cognitive impairment, and psychopharmacological studies suggest that dopamine receptor antagonists could aggravate the cognitive impairment in patients with schizophrenia (Eisenegger et al., 2014, Nakajima et al., 2013).
Dopamine β-hydroxylase (DβH) is the rate-limiting enzyme for the conversion of dopamine (DA) to norepinephrine (NE) (Condray and Yao, 2011, Friedman et al., 1999), and it may be involved in maintaining the DA/NE balance in the brain. DβH is localized within vesicles of central noradrenergic and adrenergic neurons as well as peripheral noradrenergic (sympathetic) neurons and adrenomedullary neurosecretory cells (Weinshilboum, 1978). Because the DβH enzyme is released from vesicles during sympathetic activity, the enzyme activity and DβH immunoreactive protein can be measured in the serum or plasma (Dunnette and Weinshilboum, 1976, O'Connor et al., 1994, O'Connor et al., 1983).
Plasma DβH activity (pDßH) is highly heritable and stable trait. While it varies widely across unrelated individuals (Weinshilboum et al., 1973), it is remarkably stable within individuals (Cubells and Zabetian, 2004). Polymorphic variations at the DBH gene, which encodes DβH, have been reported to be associated with cognitive function (Greenwood et al., 2014, Parasuraman et al., 2005). The DBH single nucleotide polymorphism, − 1021C > T (rs1611115), located in the 5′ upstream region of DBH, accounts for 30–50% of the variance in plasma DβH activity across samples from European-American, African-American, and Japanese individuals (Zabetian et al., 2001). In patients with attention-deficit/hyperactivity disorder (ADHD), rs1611115 significantly associated with cognitive function (Kieling et al., 2008). The ins allele, which contains the 19-bp sequence absent in the del allele and associates with higher plasma pDβH (Cubells et al., 2000), corresponded to poorer performance (Hui et al., 2017, Hui et al., 2013). Taken together, these findings suggest a role of DBH gene polymorphisms in cognitive function.
While population genetic data on the DBH gene and pDβH activity have been reported in European Americans (Zabetian et al., 2001), African Americans (Tang et al., 2007, Zabetian et al., 2001), Japanese (Zabetian et al., 2001) and Indian South Asians (Bhaduri and Mukhopadhyay, 2008) samples, no such study has yet been conducted in the Han Chinese population. The possible roles of pDβH activity and DBH polymorphisms in cognitive function and symptomatic severity in schizophrenia also need to be investigated further, in light of the observations that lower cerebrospinal fluid (CSF) levels of DβH associate with better pre-morbid adjustment in schizophrenia (Sternberg et al., 1983, Sternberg et al., 1982, van Kammen et al., 1994), and with better response to first-generation anti-psychotic medications (Sternberg et al., 1983, Sternberg et al., 1982). Therefore, the first aim of the current study was to investigate the association between DBH (rs1611115 and rs1108580) and pDβH activity in Han Chinese patients. The second aim was to examine the association among pDβH activity, DBH genotype and cognitive function in patients with schizophrenia.
Section snippets
Subjects
The research subjects included two hundred patients with schizophrenia recruited from Beijing Anding Hospital. All patients met the following inclusion criteria: (1) age 18–60 years, Han Chinese ethnicity; (2) confirmed DSM-IV diagnosis of schizophrenia; and (3) the total scores of PANSS between 60 and 120 at baseline. The exclusion criteria were as follows: had received electroconvulsive therapy within past 60 days; current substance abuse; pregnancy; significant medical conditions including
Patient characteristics
A total of 200 patients with schizophrenia were recruited in this study. On average, the subjects were 26.6 (SD = 9.4) years old, and 96 (48%) were male. The total duration of schizophrenia was 31.9 (SD = 32.34) months, the average age of onset was 23.85 (SD = 9.06) years old and the average education attainment was 12.09 (SD = 3.07) years. However, only 96 patients completed assessments after 8 weeks.
Thirty-two patients (16%) were treated mainly with first-generation antipsychotic medications: 28
Discussion
To our knowledge, this is the first report to investigate the association between DBH genotype and pDβH activity in Han Chinese subjects. We also examined the relationship among DBH gene polymorphisms, pDβH activity and cognitive function in patients with schizophrenia. We had three main findings: (1) There was a significant association between pDβH activity and DBH gene polymorphism, rs1611115, which account for 12.6% of the variance in pDβH activity. (2) There was a nominal positive
Role of funding source
This project was funded by the National Natural Science Fund of China (Grant no. 81071082) and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (Grant no. ZYLY 201403).
Contributors
Yi-Lang Tang, Wen-Biao Li, Pei-Xian Mao, Yun Ma and Zuo-Li Sun were responsible for study design, statistical analysis and manuscript preparation. Yun Ma, Xue Yang and Pei-Xian Mao were responsible for recruiting the patients, performing the clinical rating and collecting the samples. Zuo-Li Sun, Jing He and Jun Li were responsible for the DBH activity assay and DBH genotyping. Yi-Lang Tang was involved in editing the manuscript and providing the funding for the study. Joseph F. Cubells were
Conflict of interest
Dr. Yi-Lang Tang has received a pilot research funding on bipolar disorder and decision making from Janssen Pharmaceuticals from 2014 to 2015.
Acknowledgment
We would like to thank all the patients who participated in this study. We appreciate their time, cooperation and donating biological samples. We would also like to thank Ms. Honghong Zhi, the research coordinator, for her wonderful job.
References (42)
Catecholamine influences on dorsolateral prefrontal cortical networks
Biol. Psychiatry
(2011)- et al.
Role of gene-gene/gene-environment interaction in the etiology of eastern Indian ADHD probands
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
(2011) - et al.
Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the Repeatable Battery for the Assessment of Neuropsychological Status
Psychiatry Res.
(2004) - et al.
The role of norepinephrine in the pathophysiology of cognitive disorders: potential applications to the treatment of cognitive dysfunction in schizophrenia and Alzheimer's disease
Biol. Psychiatry
(1999) - et al.
Longitudinal study of symptoms and cognitive function in chronic schizophrenia
Schizophr. Res.
(2003) - et al.
Association between DBH 19 bp insertion/deletion polymorphism and cognition in first-episode schizophrenic patients
Schizophr. Res.
(2013) - et al.
Association between DBH 19bp insertion/deletion polymorphism and cognition in schizophrenia with and without tardive dyskinesia
Schizophr. Res.
(2017) - et al.
Defining a cognitive function decrement in schizophrenia
Biol. Psychiatry
(2005) - et al.
Genotype-independent decrease in plasma dopamine beta-hydroxylase activity in Alzheimer's disease
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
(2013) - et al.
The potential role of dopamine D3 receptor neurotransmission in cognition
Eur. Neuropsychopharmacol.
(2013)
A single nucleotide polymorphism at DBH, possibly associated with attention-deficit/hyperactivity disorder, associates with lower plasma dopamine beta-hydroxylase activity and is in linkage disequilibrium with two putative functional single nucleotide polymorphisms
Biol. Psychiatry
Cognitive impairment in first-episode drug-naïve patients with schizophrenia: relationships with serum concentrations of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus
Am. J. Hum. Genet.
The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine beta-hydroxylase activity
Am. J. Hum. Genet.
Regulatory polymorphisms in human DBH affect peripheral gene expression and sympathetic activity
Circ. Res.
Correlation of plasma dopamine beta-hydroxylase activity with polymorphisms in DBH gene: a study on Eastern Indian population
Cell. Mol. Neurobiol.
Cognition, dopamine and bioactive lipids in schizophrenia
Front. Biosci. (Schol. Ed.)
Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology
Psychopharmacology
Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation
Hum. Genet.
A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia
Mol. Psychiatry
Human serum dopamine beta-hydroxylase: correlation of enzymatic activity with immunoreactive protein in genetically defined samples
Am. J. Hum. Genet.
Cited by (0)
- 1
Current address: Department of Neurology, The First Hospital of Yulin City, Yulin, Shaanxi Province 719000, China.
- 2
Current address: Harbin First Specialty Hospital, Harbin, Heilongjiang Province 150056, China.